Market Snapshot

Hemophilia Market Forecast Year:	2022 - 2028
Hemophilia Market Historical Year:	2016 - 2021
Hemophilia Market 2021:	USD 12.1 Billion
Hemophilia Projected Market 2028:	USD 14.2 Billion
Hemophilia Market CAGR:	5.3%
Fastest Growing Region:	Asia Pacific
Largest Region:	North America

Market Synopsis:

Global Hemophilia Market is valued at USD 12.1 Billion in 2021 and is projected to attain a value of USD 14.2 Billion by 2028 at a CAGR of 5.3% during the forecast period, 2022–2028. One of the primary aspects projected to favourably impact market growth is increased R&D initiatives, particularly in the area of finding medicinal compounds. The limited treatment therapy alternatives available and the growing regulatory burden on regulatory authorities to address it result in increased R&D initiatives. Furthermore, increased public awareness campaigns and supportive actions, such as the government's proposal to begin early neonatal screening, are projected to increase the demand for Hemophilia diagnostic equipment.

The global market is expected to develop due to the rising prevalence of bleeding diseases and their increasing severity as a result of genetic evolution. Hemophilia Association of America, for example, gives patients continued treatment by launching various co-pay schemes. It is also envisaged that this will help patients manage their budgets and gain access to new items.

The recent outbreak of COVID-19 has prompted Hemophilia solution vendors to respond fast in order to meet the growing need for high-quality virus protection services. COVID-19 has engulfed the whole healthcare ecosystem, from pharmaceutical corporations to medicine producers to COVID-19 vaccine developers to health insurance and hospitals, thanks to its rapid expansion. During this time, applications like telemedicine, remote patient monitoring, and interactive medicine, as well as inpatient monitoring, are projected to gain popularity.

Growing Prevalence of Hemophilia

The key element driving the Hemophilia industry's growth is the rising number of Hemophilia cases around the world. Over 49,083 people were diagnosed with bleeding disorders in 2019, and this number is expected to rise to 400,000 by 2020-2021. Furthermore, advantageous government schemes in various countries, such as lowering the cost of Hemophilia Treatment, have influenced market growth. The availability of a wide range of therapy and drugs has boosted demand for Hemophilia treatment. Some of the most often used therapies and pharmaceuticals in Hemophilia treatment include inhibitor therapy, home therapy, free factor replacement, antifibrinolytic medicines, gene therapy, and physical therapy. These factors have had a significant beneficial impact on the growth of the Hemophilia Treatment Market.

Government Initiatives

In recent years, the rise of the Hemophilia treatment market has been assisted by expanding government programmes and aggressive campaigning. Also, medical guidelines based on COVID immunisation have improved the treatment and facilities connected to haemophilia therapy. Because of the improved life quality and overall therapy seen in Hemophilia patients, injectable administration has seen a growth rate of more than 5% in recent years. New technologies and pharmaceuticals have revolutionised the Hemophilia market perspective. Recent inventions have proven up to 80% recovery from the condition's symptoms and a 94% reduction in annual bleeding rates. These reasons have paved the way for the expansion of the Hemophilia industry.

Higher Cost

The Hemophilia sector is now being hampered by the higher prices connected with recombinant products and the problems associated with replacement therapies. Patients with Hemophilia who get replacement therapy develop problems including as viral infections like hepatitis B and C or HIV. The growth of the Hemophilia Treatment sector has been hampered by these negative actions on treating the disorder. Patients have the ability to generate inhibitors that prevent the injected clotting factor from working. Those with severe Hemophilia A have a 20-30% risk of having these inhibitors, while patients with Hemophilia B have a 2-5 percent chance of developing them. The growth of the Hemophilia therapy sector has also been influenced by these reasons.

Market Segmentation:

Global Hemophilia Market is segmented on the basis of Type into Hemophilia A, Hemophilia B, Hemophilia C, Others. Based on Treatment, the Hemophilia market segmented into On-demand and Prophylaxis. Based on Therapy, the Hemophilia Market segmented into Replacement therapy, ITI therapy and Gene therapy. Based on region, the Hemophilia Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Hemophilia Market

North America dominated the market in 2020, accounting for roughly 44.4 percent of total sales. The preliminary drivers of regional expansion are expected to be rising prevalence combined with a growing desire toward preventive treatment. People in the United States are diagnosed with this condition at a young age. Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the projection period. The important effect delivering drivers are early diagnosis of diseases in countries such as Japan, India, Indonesia, and Malaysia, as well as increased per capita use of medicines for factor VIII and IX insufficiency.

USD 5.4 Billion

Key Players:

Some of the players in the Hemophilia Market include Swedish Orphan Biovitrum AB, Sanofi SA, Pfizer, Novo Nordisk, Genentech, CSL Behring, Biogen, among other market players.

Hemophilia Market is segmented as follows:

• Type
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

• Treatment
  • On-demand
  • Prophylaxis

• Therapy
  • Replacement therapy
  • ITI therapy
  • Gene therapy

• Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Hemophilia Market is tabulated as follows:

Parameter	Details
Market Size Provided for Years	2016-2028
Base Year	2021
Historic Years	2016-2020
Forecast Years	2022-2028
Segments Covered	Type Hemophilia A Hemophilia B Hemophilia C Others Treatment On-demand Prophylaxis Therapy Replacement therapy ITI therapy Gene therapy Region North America Latin America Europe Asia Pacific Middle East & Africa
Region & Counties Covered	North America U.S. Canada Mexico Europe U.K France Germany Italy Spain Rest Of Europe Asia Pacific China Japan India South Korea South East Asia Rest Of Asia Pacific Latin America Brazil Argentina Rest Of Latin America Middle East & Africa GCC Cuntries South Africa Rest Of Middle East & Africa
Companies Covered	Shire (Baxalta); CSL Behring; Pfizer Inc.; Bayer AG; BioMarin Spark Therapeutics Inc.; Genzyme Corporation; Chugai Pharmaceutical Co. Ltd.; Novo Nordisk A/S.; and Octapharma AG
Report Coverage	Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis